(S)-2-(((E)-((S)-3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazol-1-yl)((4-chlorophenyl)sulfonamido)methylene)amino)-3-methylbutanamide
(S)-2-(((E)-((S)-3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazol-1-yl)((4-chlorophenyl)sulfonamido)methylene)amino)-3-methylbutanamide
CAS: 1392116-14-1
Molecular Formula: C27H27Cl2N5O3S
(S)-2-(((E)-((S)-3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazol-1-yl)((4-chlorophenyl)sulfonamido)methylene)amino)-3-methylbutanamide - Names and Identifiers
(S)-2-(((E)-((S)-3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazol-1-yl)((4-chlorophenyl)sulfonamido)methylene)amino)-3-methylbutanamide - Physico-chemical Properties
| Molecular Formula | C27H27Cl2N5O3S |
| Molar Mass | 572.51 |
| Density | 1.40±0.1 g/cm3(Predicted) |
| Boling Point | 721.6±70.0 °C(Predicted) |
| Solubility | DMSO |
| pKa | 10.63±0.60(Predicted) |
| Storage Condition | 2-8℃ |
| MDL | MFCD30533451 |
| Use | JD-5037 is a novel, peripherally restricted CB1R antagonist with an IC50 of 1.5 nM. |
| Target | CB1 |
| In vivo study | JD5037 (3 mg/kg/d, i.p.) induces equal reductions in body weight, attenuates the HFD-induced hyperglycemia, and reduces the HFD-induced hepatic injury and steatosis in obese Magel2-null mice. JD5037 (3 mg/kg/day, p.o.) significantly reduces the size of tumors and abrogates the tumor in DEN-treated mice. JD5037 attenuates the AEA levels in HCC samples from mice. |
(S)-2-(((E)-((S)-3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazol-1-yl)((4-chlorophenyl)sulfonamido)methylene)amino)-3-methylbutanamide - Reference
| Reference Show more | 1. Chorvat RJ. Peripherally restricted CB1 receptor blockers. Bioorg Med Chem Lett. 2013 Sep 1;23(17):4751-60.2. Knani I, et al. Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader-Willi syndrome. Mol Metab. 2016 Oct 22;5(12):1187-1199.3. Mukhopadhyay B, et al. Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms. Hepatology. 2015 May;61(5):1615-26. |
(S)-2-(((E)-((S)-3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazol-1-yl)((4-chlorophenyl)sulfonamido)methylene)amino)-3-methylbutanamide - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 1.747 ml | 8.733 ml | 17.467 ml |
| 5 mM | 0.349 ml | 1.747 ml | 3.493 ml |
| 10 mM | 0.175 ml | 0.873 ml | 1.747 ml |
| 5 mM | 0.035 ml | 0.175 ml | 0.349 ml |
Last Update：2024-01-02 23:10:35
(S)-2-(((E)-((S)-3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazol-1-yl)((4-chlorophenyl)sulfonamido)methylene)amino)-3-methylbutanamide - Reference Information
| biological activity | JD-5037 is a cannabinoid-1 receptor blocker, the IC50 value for CB1 receptor is 2 nM, and the IC50 value for CB2 receptor is greater than 1000 nM. |
| target | TargetValue CB1 receptor () 2 nM |
| Target | Value |
| CB1 receptor () | 2 nM |
| in vivo study | jd5037 (3 mg/kg/d, I. p.) induces equal reductions in body weight, attenuates the HFD-induced hyperglycemia, and reduces the HFD-induced hepatic injury and steatosis in obese Magel2-null mice. jd5037 (3 mg/kg/day, P. o.) significantly reduces the size of tumors and abrogates the tumor in DEN-treated mice. JD5037 attenuates the AEA levels in HCC samples from mice. |
Last Update：2024-04-10 22:29:15
Supplier List
Spot supply
Product Name: (S)-2-(((E)-((S)-3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazol-1-yl)((4-chlorophenyl)sulfonamido)methylene)amino)-3-methylbutanamide Visit Supplier Webpage Request for quotationCAS: 1392116-14-1
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: (S)-2-(((E)-((S)-3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazol-1-yl)((4-chlorophenyl)sulfonamido)methylene)amino)-3-methylbutanamide Visit Supplier Webpage Request for quotationCAS: 1392116-14-1
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History